344 related articles for article (PubMed ID: 12586591)
1. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Ball HG; Hoffman J; Warshal D; DeGeest K; Moore DH
Gynecol Oncol; 2003 Feb; 88(2):130-5. PubMed ID: 12586591
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
Verschraegen CF; Sittisomwong T; Kudelka AP; Guedes Ed; Steger M; Nelson-Taylor T; Vincent M; Rogers R; Atkinson EN; Kavanagh JJ
J Clin Oncol; 2000 Jul; 18(14):2733-9. PubMed ID: 10894873
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.
Markman M; Zanotti K; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2003 Dec; 91(3):573-6. PubMed ID: 14675679
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
6. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
J Clin Oncol; 2001 Apr; 19(7):1901-5. PubMed ID: 11283121
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
Berkenblit A; Seiden MV; Matulonis UA; Penson RT; Krasner CN; Roche M; Mezzetti L; Atkinson T; Cannistra SA
Gynecol Oncol; 2004 Dec; 95(3):624-31. PubMed ID: 15581974
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study.
Katsumata N; Tsunematsu R; Tanaka K; Terashima Y; Ogita S; Hoshiai H; Kohno I; Hirabayashi K; Yakushiji M; Noda K; Taguchi T
Ann Oncol; 2000 Dec; 11(12):1531-6. PubMed ID: 11205459
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
Francis P; Schneider J; Hann L; Balmaceda C; Barakat R; Phillips M; Hakes T
J Clin Oncol; 1994 Nov; 12(11):2301-8. PubMed ID: 7964944
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.
Piccart MJ; Gore M; Ten Bokkel Huinink W; Van Oosterom A; Verweij J; Wanders J; Franklin H; Bayssas M; Kaye S
J Natl Cancer Inst; 1995 May; 87(9):676-81. PubMed ID: 7752272
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Ferraresi V; Milella M; Vaccaro A; D'Ottavio AM; Papaldo P; Nisticò C; Thorel MF; Marsella A; Carpino A; Giannarelli D; Terzoli E; Cognetti F
Am J Clin Oncol; 2000 Apr; 23(2):132-9. PubMed ID: 10776972
[TBL] [Abstract][Full Text] [Related]
13. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum.
du Bois A; Lück HJ; Buser K; Meerpohl HG; Sessa C; Klaassen U; Meden H; Bochtler H; Diergarten K
Eur J Cancer; 1997 Mar; 33(3):379-84. PubMed ID: 9155520
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel in the treatment of ovarian cancer.
Kavanagh JJ
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):73-81. PubMed ID: 12108900
[TBL] [Abstract][Full Text] [Related]
16. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.
Coleman RL; Brady WE; McMeekin DS; Rose PG; Soper JT; Lentz SS; Hoffman JS; Shahin MS
Gynecol Oncol; 2011 Jul; 122(1):111-5. PubMed ID: 21497382
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
[TBL] [Abstract][Full Text] [Related]
19. A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
Monk BJ; Kauderer JT; Moxley KM; Bonebrake AJ; Dewdney SB; Secord AA; Ueland FR; Johnston CM; Aghajanian C
Gynecol Oncol; 2018 Dec; 151(3):422-427. PubMed ID: 30309721
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
Catimel G; Verweij J; Mattijssen V; Hanauske A; Piccart M; Wanders J; Franklin H; Le Bail N; Clavel M; Kaye SB
Ann Oncol; 1994 Jul; 5(6):533-7. PubMed ID: 7918125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
